Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Gumeniuk, S. Panchuk (Kyiv, Ukraine). Decametoxine efficiency in the treatment of infectious exacerbation of asthma. Eur Respir J 2014; 44: Suppl. 58, 3343

Member's Comments

No comment yet.

Related content which might interest you: Spectrum of viral pathogens in adults patients with infectious exacerbations of bronchial asthma Source: Annual Congress 2013 –Viral infections Year: 2013 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Identification of viral species in asthma patients with and without aspirin hypersensitivity Source: Annual Congress 2013 –Viral infections Year: 2013 Antioxidant efficiency in the treatment of asthma exacerbations Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Adult asthma patients reporting exacerbations triggered by upper airway infection have increased total IgE and sensitization to HDM Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 The airway microbiota is significantly altered in subjects with eosinophilic asthma Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Asthma patients hospitalized with influenza lack mucosal and systemic type 2 inflammation Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Use of β-blockers and the risk of asthma exacerbations Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Benralizumab effect on blood basophil counts in adults with uncontrolled asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model) Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Prevention of the recurrent acute respiratory viral infections and virus-induced exacerbation of bronchial asthma in children Source: Annual Congress 2013 –Preschool wheeze Year: 2013 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014